VEGF inhibition and metastasis: Possible implications for antiangiogenic therapy

Cancer Biology and Therapy

Volumn 8, Issue 13, 2009, Pages 1212-1213

  English, Bevin C ^a   Price, Douglas K ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; DC101; Hypoxia; Invasiveness; Metastasis; Sunitinib; VEGF

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY DC101; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER INVASION; COLON CANCER; DISTANT METASTASIS; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PHENOTYPE; SHORT SURVEY; TREATMENT OUTCOME; ANIMAL; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; DISEASE MODELS, ANIMAL; HUMANS; INDOLES; NEOPLASM METASTASIS; NEOPLASMS; PYRIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68149178579     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.13.8918     Document Type: Short Survey

References (8)

1. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-49.
2. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westpha M, Deen DF, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306-14.
3. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9.
4. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31.
5. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999; 59:5412-6.
6. Drevs J, Hofmann I, Hugenshmidt H, Wittig C, Madjar H, Müller M, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60:4819-24.
7. Kieran MW, Folkman J, Heymach J. Angiogenesis inhibitors and hypoxia. Nature Medicine 2003; 9:1104.
8. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3:347-61.